Skip to content
Disclosery

Merck & Co., Inc.

Follow

13F filer, CIK 310158, RAHWAY, NJ

Merck & Co., Inc. reported $215,600,331 across 13 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-13. Its ten largest share positions make up 99.69% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001691304-25-000005

Period
2025-06-30
Reported value
$216M
Holdings
13
Top 10 weight
99.69%
New
1
Sold out
0

Part of the filer group Merck & Co., Inc.

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
HURAnew+13,950$31.1K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

None.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0001691304-25-000005, largest first. % of portfolio is the value over $215,600,331, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PSNLPERSONALIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 14,044,943 shares; 2025Q1: 14,044,943 shares; 2025Q2: 14,044,943 shares 14,044,943$92.1M42.73%0Timeline
MRNAMODERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 2,308,190 shares; 2025Q1: 2,308,190 shares; 2025Q2: 2,308,190 shares 2,308,190$63.7M29.54%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 772,165 shares; 2025Q1: 772,165 shares; 2025Q2: 772,165 shares 772,165$33.7M15.63%0Timeline
ENTRADA THERAPEUTICS INCENTRADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,739,768 shares; 2025Q1: 1,739,768 shares; 2025Q2: 1,739,768 shares 1,739,768$11.7M5.42%0
ALECALECTOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 3,545,719 shares; 2025Q1: 3,545,719 shares; 2025Q2: 3,545,719 shares 3,545,719$4.96M2.3%0Timeline
EVAXION BIOTECH A/SEVAXION BIOTECH A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 542,279 shares; 2025Q1: 1,214,126 shares; 2025Q2: 1,214,126 shares 1,214,126$2.97M1.38%0
SUTRO BIOPHARMA INCSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 2,723,509 shares; 2025Q1: 2,723,509 shares; 2025Q2: 2,723,509 shares 2,723,509$1.94M0.9%0
LAVA THERAPEUTICS NVLAVA THERAPEUTICS NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,149,345 shares; 2025Q1: 1,149,345 shares; 2025Q2: 1,149,345 shares 1,149,345$1.52M0.7%0
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 93,414 shares; 2025Q1: 93,414 shares; 2025Q2: 93,414 shares 93,414$1.31M0.61%0Timeline
XLOXilio Therapeutics Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,483,758 shares; 2025Q1: 1,483,758 shares; 2025Q2: 1,483,758 shares 1,483,758$1.01M0.47%0Timeline
CARMCARISMA THERAPEUTICS INC COMQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 1,473,240 shares; 2025Q1: 1,473,240 shares; 2025Q2: 1,473,240 shares 1,473,240$577K0.27%0Timeline
NEUPNEUPHORIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: 10,027 shares; 2025Q1: 10,027 shares; 2025Q2: 10,027 shares 10,027$71.2K0.03%0Timeline
HURATUHURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not loaded; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 13,950 shares 13,950$31.1K0.01%newTimeline

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001691304-25-000005 base2025-08-13acceptance time not in the bulk data set